NEW YORK (GenomeWeb News) – Veracyte today increased the proposed maximum aggregate offering amount for its planned initial public offering to $81.1 million.

In an amended Form S-1 filed with the US Securities and Exchange Commission today, the molecular cytology firm also announced its preliminary third quarter financial results.

Veracyte said in the SEC filing that it expects to offer 4.7 million shares at a price between $13 and $15 per share, with the intention of raising net proceeds of $58.7 million at the midpoint price of $14 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.